What is Cagrilintide?
Cagrilintide is an amylin analog. Amylin is a pancreatic hormone involved in satiety and gastric-emptying biology, so cagrilintide sits beside incretin drugs rather than inside the GLP-1 family.[4]
As monotherapy, cagrilintide has phase 2 dose-finding evidence for weight management. Its most visible development path is co-administered cagrilintide plus semaglutide, often called CagriSema.[4][5][6]
Recent REDEFINE publications strengthen the human evidence for CagriSema. Cagrilintide-alone and CagriSema results should stay separate because the combination includes semaglutide.[7][8][5]
What Cagrilintide is investigated for
Cagrilintide evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Semaglutide combination weight loss
Injectable
Semaglutide combination weight loss
Injectable
Combination weight loss is the most visible CagriSema use case, but the combination remains separate from cagrilintide monotherapy and regulatory approval status.[7][3][2]
Monotherapy weight reduction
Injectable
Monotherapy weight reduction
Injectable
Cagrilintide monotherapy has human weight-management evidence, while the largest effects currently come from the semaglutide combination program.[4][14][1]
Type 2 diabetes glycemic control
Injectable
Type 2 diabetes glycemic control
Injectable
Appetite control and satiety
Injectable
Appetite control and satiety
Injectable
Satiety is a plausible cagrilintide effect within weight management, but it should not be framed as a standalone approved use.[4][15]
Evidence snapshot
Overall confidence
Cagrilintide has credible late-stage human data, especially in combination with semaglutide. The main interpretation issue is keeping monotherapy and CagriSema evidence separate.[4][7]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human evidence includes cagrilintide monotherapy dose-finding, cagrilintide plus semaglutide studies, type 2 diabetes combination data, and published REDEFINE results.[4][5][6][7][8]
Animal / preclinical
Preclinical and receptor-mechanism research supports amylin and calcitonin receptor biology, but the practical confidence comes from human weight-management trials.[30][19][17]
Mechanism support
Amylin-analog activity gives a coherent rationale for satiety and body-weight effects, and combination trials pair that biology with semaglutide rather than replacing GLP-1 signaling.[4][5][17]
Forms & administration
Cagrilintide is an investigational subcutaneous medicine, with a cartridge presentation for NovoPen 4. Cagrilintide alone and cagrilintide–semaglutide combinations have separate dosing contexts. The device name does not identify its contents, cartridge strength or preparation requirements.[4][5][7][38]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
What to expect
First weeks
Fullness can come sooner and appetite may be easier to manage, especially when cagrilintide is paired with semaglutide.[5][4]
3-6 months
Weight and waist reductions can become more visible as fullness and appetite control build, with larger effects in cagrilintide-semaglutide combination data.[4][7]
1 year
Weight and waist reductions can persist with continued treatment, especially in combination studies, while appetite control remains the main felt effect.[7][8]
After stopping
Fullness may fade and appetite can move back toward baseline after pausing or stopping; weight and waist changes may soften without ongoing amylin-analog exposure.[4][15]
Safety profile
Cagrilintide safety is still investigational and route-specific. The practical safety focus is GI tolerability, combination effects with semaglutide, hypoglycemia considerations in diabetes trials, and the lack of approved-product labeling.[4][6][3]
Who Cagrilintide is not for
Route-specific avoid and medical-review notes:
Drug & supplement interactions
Documented interactions are separated from theoretical or route-specific cautions.
Theoretical interactions
- Semaglutide, GLP-1, or other satiety drugs
Cagrilintide adds amylin-pathway satiety effects on top of GLP-1 therapy; pairing it with semaglutide or other GLP-1, GIP, or amylin weight-loss drugs can compound nausea, vomiting, diarrhea, constipation, and appetite-suppression effects, and safety rules outside studied cagrilintide-semaglutide protocols are not established.[5][7]
Pairing notes
Works well with
Not recommended with
Cagrilintide adds amylin-mediated satiety to tirzepatide's GIP and GLP-1 effects. This combination falls outside studied CagriSema and has no established combined dosing or safety framework.[7][35]
Cagrilintide adds amylin-mediated satiety to retatrutide's GIP, GLP-1, and glucagon effects. The combination is investigational and has no established combined dosing or safety framework.[7][36][37]
Regulatory status
United States
United States: not FDA-approved for human use as a drug. FDA also states cagrilintide cannot be used in compounding under federal law.[1][3][2]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Injectable | Not Approved Cagrilintide and CagriSema are not FDA-approved for human use as drug products in the United States.[1][3][2] | Not Listed FDA states cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition.[2] |
Injectable
FDA drug approval
Not ApprovedCagrilintide and CagriSema are not FDA-approved for human use as drug products in the United States.[1][3][2]
503A compounding
Not ListedFDA states cagrilintide cannot be used in compounding under federal law and has not been found safe and effective for any condition.[2]
International
International status is country-specific and should be checked against local medicine registers before any product or claim is assumed lawful.
Sports & competition
For athletes, cagrilintide may fall under WADA non-approved-substance rules because it is not approved by a governmental regulatory health authority for human therapeutic use.[1]
How it works
Cagrilintide is a long-acting amylin analog. Its core mechanism is satiety signaling, not GLP-1 duplication, with brain amylin-receptor pathways supporting food-intake reduction. That keeps it in amylin/satiety context.[28][19]
Cagrilintide-alone data show the amylin pathway can move body weight, while CagriSema pairs that pathway with semaglutide's GLP-1 appetite, gastric-emptying, and glucose effects.[4][5][7]
Combination results still belong to the combination: weight loss, nausea, appetite suppression, and tolerability in CagriSema trials cannot be assigned cleanly to cagrilintide alone or generalized to other amylin drugs.[5][7]
Research gaps & open questions
What the current literature has not yet settled about Cagrilintide:
Regulatory review and approved labeling are still needed to define safe dosing, warnings, contraindications, manufacturing standards, and real-world use.[1][3]
Trials need to separate cagrilintide's effects from semaglutide's effects; results from CagriSema should not be treated as proof for cagrilintide alone.[4][7]
Longer studies should show what happens during maintenance and after stopping, including changes in muscle mass and risks involving the gut, gallbladder, diabetes medications, and understudied populations.[10][11]
Common questions
Is cagrilintide a GLP-1 drug?
Is CagriSema FDA-approved?
Myths & misconceptions
Myth
Amylin analogs and GLP-1 agonists are the same kind of peptide.
Myth
CagriSema results prove cagrilintide alone works the same way.
Reality
Combination studies include semaglutide, so they cannot be used as cagrilintide-alone proof.[7]
History & discovery
Cagrilintide's history starts in long-acting amylin-analog development, not GLP-1 development. It became prominent because CagriSema paired cagrilintide's satiety biology with semaglutide's GLP-1 biology, a distinction that now dominates public attention.[28][26][4][5]
Development, dose-finding, and early cagrilintide-plus-semaglutide work positioned cagrilintide as an amylin satiety drug with a separate rationale from GLP-1 therapy before larger combination trials.[28][4][5]
Type 2 diabetes, REDEFINE, and mechanistic publications made the CagriSema program the main public evidence anchor while keeping combination results separate from cagrilintide-alone claims and informal stacking.[6][7][8][19]
38 citations
Show citationsHide citations
- [1]openFDA Drugs@FDA query for cagrilintideopenFDA / U.S. Food and Drug Administration. database query.
- [2]FDA's concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration. regulatory.
- [3]openFDA Drugs@FDA query for CagriSemaopenFDA / U.S. Food and Drug Administration. database query.
- [4]Once-weekly cagrilintide for weight management in people with overweight and obesityThe Lancet. human clinical.
- [5]Cagrilintide plus semaglutide in people with overweight or obesity: a randomised phase 1b trialThe Lancet. human clinical.
- [6]Cagrilintide and semaglutide co-administration in type 2 diabetesThe Lancet. human clinical.
- [7]Coadministered cagrilintide and semaglutide in adults with overweight or obesityNew England Journal of Medicine. human clinical.
- [8]Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetesNew England Journal of Medicine. human clinical.
- [9]Cagrilintide-semaglutide for weight management in east Asian individuals with overweight or obesityPeer-reviewed clinical trial. human clinical.
- [10]REDEFINE 1 CagriSema obesity trial registry recordClinicalTrials.gov. clinical trial registry.
- [11]REDEFINE 2 CagriSema type 2 diabetes obesity trial registry recordClinicalTrials.gov. clinical trial registry.
- [12]Cagrilintide weight-management trial registry recordClinicalTrials.gov. clinical trial registry.
- [13]Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous CagrilintideClinical pharmacokinetics, 2026. human clinical.
- [14]Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-RegressionDiabetes, obesity & metabolism, 2026. review.
- [15]Long-acting amylin-related peptides as therapies for obesity and type 2 diabetesPeptides, 2026. review.
- [16]CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1Hypertension (Dallas, Tex. : 1979), 2026. human clinical.
- [17]Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptorsActa pharmacologica Sinica, 2026. in vitro.
- [18]Characterization of 0839 - A tool compound for pre-clinical mode-of-action studies of amylin analogues such as cagrilintideLife sciences, 2025. in vitro.
- [19]Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3EBioMedicine, 2025. animal.
- [20]Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptorsNature communications, 2025. in vitro.
- [21]A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy BalancebioRxiv : the preprint server for biology, 2025. animal.
- [22]Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-AnalysisIndian journal of endocrinology and metabolism, 2024. review.
- [23]Amylin analogs for the treatment of obesity without diabetes: present and futureExpert review of clinical pharmacology, 2024. review.
- [24]Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participantsDiabetes, obesity & metabolism, 2024. human clinical.
- [25]Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysisBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. review.
- [26]Cagrilintide: A Long-Acting Amylin Analog for the Treatment of ObesityCardiology in review, 2024. review.
- [27]Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical modelsBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022. animal.
- [28]Development of Cagrilintide, a Long-Acting Amylin AnalogueJournal of medicinal chemistry, 2021. in vitro.
- [29]Cagrilintide plus semaglutide for obesity managementLancet (London, England), 2021. review.
- [30]AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective AgonistsThe Journal of pharmacology and experimental therapeutics, 2021. in vitro.
- [31]Emerging pharmacotherapies for obesity: A systematic reviewPharmacological reviews, 2025. review.
- [32]Weight management treatment in obesityMedicina clinica, 2025. review.
- [33]What is the pipeline for future medications for obesity?International journal of obesity (2005), 2025. review.
- [34]WEGOVY (semaglutide) injection and tablets prescribing informationU.S. Food and Drug Administration, 2026. regulatory.
- [35]ZEPBOUND (tirzepatide) injection prescribing informationU.S. Food and Drug Administration, 2026. regulatory.
- [36]Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trialLancet (London, England), 2026. human clinical.
- [37]Understanding responsibilities for unapproved peptide productsTherapeutic Goods Administration. official guidance.
- [38]A dose-finding trial of NNC0174-0833 (cagrilintide): EudraCT 2018-001945-14 resultsEU Clinical Trials Register. clinical trial registry.


